Evidence map›Paper›PMID 33981865›Full record

ReviewClinical and translational radiation oncology2021

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M Ryckman, Bradley N Reames, Kelsey A Klute, William A Hall, Michael J Baine, May Abdel-Wahab, Chi Lin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jeffrey M RyckmanDepartment of Radiation Oncology, West Virginia University Cancer Institute, Parkersburg, WV, USA.
Bradley N ReamesDepartment of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Kelsey A KluteDepartment of Medical Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
William A HallDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Michael J BaineDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
May Abdel-WahabDivision of Human Health, International Atomic Energy Agency, Vienna, Austria.
Chi LinDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

Indexed as

Pancreatic cancerStereotactic body radiotherapyTotal neoadjuvant therapy

Identifiers

PMID33981865
PMCPMC8085778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.